Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Lantern Pharma Inc.
NRG Oncology
Pfizer
BerGenBio ASA
Masonic Cancer Center, University of Minnesota
National Cancer Institute (NCI)
Alliance for Clinical Trials in Oncology
SWOG Cancer Research Network
Emory University
National Taiwan University Hospital
University of Rochester
Sun Yat-sen University
University of British Columbia
Shanghai Pulmonary Hospital, Shanghai, China
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
National Institutes of Health Clinical Center (CC)
Hunan Province Tumor Hospital
Samsung Medical Center
National Institutes of Health Clinical Center (CC)
Novartis
Guangzhou Institute of Respiratory Disease
Hospital Israelita Albert Einstein
Fudan University
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Northwestern University
Sun Yat-sen University
Fujian Cancer Hospital
Shanghai Pulmonary Hospital, Shanghai, China
Hunan Cancer Hospital
Shanghai Pulmonary Hospital, Shanghai, China
Case Comprehensive Cancer Center
Helix BioPharma Corporation
Hoosier Cancer Research Network
Swiss Cancer Institute
University of Colorado, Denver
Abramson Cancer Center at Penn Medicine
Tianjin Medical University Cancer Institute and Hospital
Henan Cancer Hospital
Barbara Ann Karmanos Cancer Institute
Novartis
Novartis
Samsung Medical Center
Novartis
Albert Einstein College of Medicine
Morphotek
Henan Cancer Hospital
University Health Network, Toronto